ycbd_8k.htm

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) April 7, 2022

ycbd_8kimg1.jpg

cbdMD, INC.

(Exact name of registrant as specified in its charter)

 

North Carolina

 

001-38299

 

47-3414576

(State or other jurisdiction of incorporation or organization)

 

(Commission File Number)

 

(I.R.S. Employer Identification No.)

 

8845 Red Oak Blvd, Charlotte, NC  28217(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (704) 445-3060

 _____________________________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

common

 

YCBD

 

NYSE American

8% Series A Cumulative Convertible Preferred Stock

 

YCBD PR A

 

NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement. 

 

As part of ongoing initiatives to cost optimization initiatives of cbdMD, Inc. (the “Company”), on April 7, 2022 Company entered into an equipment purchase agreement to sell substantially all of its manufacturing equipment to a subsidiary of Steady State, LLC (“Steady State”) and simultaneously entered into a manufacturing and supply agreement with the Steady State whereby Steady State will manufacture certain products for the Company.  Steady State (and its subsidiaries) is an existing qualified supplier of the Company.  The equipment sale is initially valued at approximately $1.8 million for accounting purposes, the sale price consisting of products to be provided to the Company under the manufacturing and supply agreement and $1.4 million of which the Company shall invest into Steady State in the form of an equity investment consistent with the terms of Steady State’s recently completed financing.  

 

The foregoing description of the terms of the equipment purchase agreement is qualified in its entirety by reference to the full text of the agreement, which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 or via an amendment to this Current Report on Form 8-K.

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

cbdMD, Inc.

 

 

 

Date: April 12, 2022

By:

/s/ T. Ronan Kennedy

 

 

T. Ronan Kennedy, Chief Financial Officer

 

 

 

 

3